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Abstract
Parkinson’s disease (PD), the second most prevalent neurodegenerative disease after Alzheimer’s disease, is linked to the
gradual loss of dopaminergic neurons in the substantia nigra. Disease loci causing hereditary forms of PD are known, but
most cases are attributable to a combination of genetic and environmental risk factors. Increased incidence of PD is
associated with rural living and pesticide exposure, and dopaminergic neurodegeneration can be triggered by neurotoxins
such as 6-hydroxydopamine (6-OHDA). In C. elegans, this drug is taken up by the presynaptic dopamine reuptake
transporter (DAT-1) and causes selective death of the eight dopaminergic neurons of the adult hermaphrodite. Using a
forward genetic approach to find genes that protect against 6-OHDA-mediated neurodegeneration, we identified tsp-17,
which encodes a member of the tetraspanin family of membrane proteins. We show that TSP-17 is expressed in
dopaminergic neurons and provide genetic, pharmacological and biochemical evidence that it inhibits DAT-1, thus leading
to increased 6-OHDA uptake in tsp-17 loss-of-function mutants. TSP-17 also protects against toxicity conferred by excessive
intracellular dopamine. We provide genetic and biochemical evidence that TSP-17 acts partly via the DOP-2 dopamine
receptor to negatively regulate DAT-1. tsp-17 mutants also have subtle behavioral phenotypes, some of which are conferred
by aberrant dopamine signaling. Incubating mutant worms in liquid medium leads to swimming-induced paralysis. In the L1
larval stage, this phenotype is linked to lethality and cannot be rescued by a dop-3 null mutant. In contrast, mild paralysis
occurring in the L4 larval stage is suppressed by dop-3, suggesting defects in dopaminergic signaling. In summary, we show
that TSP-17 protects against neurodegeneration and has a role in modulating behaviors linked to dopamine signaling.
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Introduction
Parkinson’s Disease (PD) is the second most common neurode-
generative disease, after Alzheimer’s disease, and affects ,2% of
the population aged over 65 years. Loss of dopaminergic neurons
is a pathological hallmark of PD [1,2] and aspects of this
neurodegeneration have been modeled in C. elegans [3,4]. The
etiology of PD is largely unknown and its heritability is generally
rather low; however ,5–10% of cases are associated with
monogenetically inherited mutations [5]. Approximately 15
disease loci are known, most of which are conserved in C. elegans
[6,7]. The vast majority of PD cases are ‘sporadic’ with no clear
family history. Besides aging, epidemiological studies have shown
risk factors for ‘sporadic’ PD to include a long-term history of rural
living, farming, well-water drinking and pesticide exposure. The
most extreme examples of toxin-induced PD-like symptoms were
linked to the accidental exposure to MPTP (N-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine). Similar to sporadic PD cases, PD-like
symptoms resulting from MPTP exposure could be alleviated by
administration of the dopamine precursor L-3,4-dihydrooxyphe-
nylalanine (L-DOPA) [8]. Exposure to pesticides such as paraquat
and rotenone has also been implicated in PD development [9].
The disease is therefore thought to be triggered by a combination
of environmental factors and genetic susceptibility [5].
MPTP, paraquat and rotenone all block the mitochondrial
electron transport chain, leading to oxidative damage [10], and
have been extensively used to model PD neurodegeneration. 6-
Hydroxydopamine (6-OHDA), an oxidation product of dopamine,
is another neurotoxin widely used in mammalian PD models to
induce the specific degeneration of dopaminergic neurons [11]. 6-
OHDA was initially identified as a metabolite of dopamine [12],
and there is some evidence that 6-OHDA exposure might be
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linked to PD. 6-OHDA was also identified as a naturally occurring
amine in human urine, and has been detected at higher
concentrations in PD patients [13]. Furthermore, high 6-OHDA
levels were found in postmortem brain samples from PD patients
[14]. It has been reported that 6-OHDA interaction with oxygen
results in the production of reactive oxygen species (ROS), which
in turn trigger free radical-mediated neuronal degeneration [2,12].
Other dopamine metabolites may also cause oxidative damage
[15]. Nevertheless, the mechanism by which 6-OHDA induces
neuronal degeneration remains largely unknown [16].
Although there is no treatment to prevent or halt neuronal loss,
L-DOPA administration is still one of the most effective treatments
for alleviating PD symptoms [17,18]. However, the effectiveness of
L-DOPA declines over time. Prolonged L-DOPA treatment is also
potentially neurotoxic [11,15]. Although not confirmed in a large
longitudinal study of L-DOPA use in PD patients (ELLDOPA
trial), this nevertheless remains a major concern [19].
C. elegans has been used as a model to study the structure and
function of the nervous system, which in hermaphrodite worms
consists of 302 neurons [20,21]. C. elegans dopaminergic neurons
are functionally related to those of humans. The genes driving the
biochemical processes involved in dopamine metabolism (as well
as most PD-associated loci) [6] are also highly conserved in worms
[22]. Dopaminergic neurons can be readily visualized in vivo using
appropriate GFP markers. Analogous to vertebrate systems,
dopaminergic neurons undergo neurodegeneration upon treat-
ment with 6-OHDA. It has been shown that 6-OHDA can enter
dopaminergic neurons through the DAT-1 dopamine transporter
and thus trigger their degeneration [3]. The exact type of cellular
death that occurs following 6-OHDA intoxication is unknown.
Electron microscopy has shown apoptotic-like condensed chro-
matin structures in dying neurons, suggesting that 6-OHDA
induces apoptosis. However, 6-OHDA-induced neurodegenera-
tion in C. elegans is independent of CED-4/Apaf1 and CED-3/
caspase, two components of the core apoptotic machinery [3]. In
an independent study, inactivation of C. elegans autophagy genes
partially suppressed 6-OHDA-induced dopaminergic death, sug-
gesting that autophagy might also be involved in this process [23].
During synaptic transmission most of the released dopamine is
transported back into the presynaptic terminal by the dopamine
reuptake transporter (DAT1) (for a review, see [24]. Therefore,
activity of this transporter affects the duration and extent of
dopamine signaling. Mammalian cell experiments led to the
identification of several proteins that interact with DAT1 to
modulate its activity, cell surface expression and trafficking. These
include protein kinase C, dopamine D2 receptors (discussed
below), SNCA and parkin [25–28]. The physiological actions of
dopamine are mediated by conserved seven-transmembrane
dopamine receptors, designated D1–5. Dopamine receptors are
coupled to guanosine triphosphate-binding proteins (G proteins)
and are classified into D1 or D2 type dopamine receptors based on
their antagonistic effect on adenylyl cyclase activity [29,30]. D1
dopamine receptors, DOP-1 in worms, are solely found in
postsynaptic dopamine-receptive cells, whereas in C. elegans the
D2 type receptors DOP-2 and DOP-3 are expressed pre and
postsynaptically, respectively [31–33].
In vertebrates, the dopamine system plays a crucial role in
regulating movement, reward and cognition. Dopamine-deficient
newborn mice die as a result of severe motor impairments [34,35].
In contrast, C. elegans mutants defective in dopamine synthesis are
viable, thus facilitating investigations into dopamine-mediated
behavior in these animals. Dopaminergic neurons in C. elegans
are required for specific, well-described and quantifiable behav-
iors, often associated with locomotion and feeding. For instance,
the basal slowing response allows worms to reduce their speed
when encountering a bacterial lawn, which is their food source
[36]. Another behavior mediated by dopamine signaling is
referred to as ‘‘swimming-induced paralysis’’ (SWIP): dat-1-
deficient worms exhibit rapid paralysis in liquid, unlike wild-type
controls [37].
Using an unbiased forward genetic approach we identified tsp-
17 as a gene that protects dopaminergic neurons from 6–OHDA-
mediated neurodegeneration. We provide evidence that TSP-17
regulates DAT-1 transporter activity. Furthermore, our results
suggest that DAT-1 regulation by TSP-17 is partly mediated by
D2 dopamine receptors.
Results
In order to find genes that protect dopaminergic neurons, we
performed a genetic screen for mutants conferring hypersensitivity
to 6-OHDA. By adapting procedures initially established by Nass
et al. [3] and using the same pdat-1::GFP reporter that highlights
dopaminergic neurons, we screened ,2500 F2 ethyl methanesul-
fonate (EMS)-mutagenized worms at the L1 developmental stage
by incubating with 10 mM 6-OHDA for 1 h. This procedure,
which is based on reduced, altered, or absent pdat-1::GFP
expression, does not lead to neurodegeneration in .95% of wild-
type worms, thus allowing the identification of mutants conferring
hypersensitivity to 6-OHDA. Of the initial five mutant candidates,
only gt1681 maintained a strong hypersensitive phenotype upon
backcrossing (Figure 1A, Figure S1). 6-OHDA-induced degener-
ation of both wild-type and gt1681 neurons exhibits the same
morphological features and pattern of degeneration initially
described by Nass et al. [3]. Axonal blebbing becomes apparent
(Figure 1B, inset, arrows) a feature also consistent with morpho-
logical changes previously observed by electron microscopy.
Worms were scored 24, 48 and 72 h after intoxication. Neurons
were lost in less than 10% of wild-type worms after 72 h. In
contrast, all dopaminergic neurons were lost in ,40% of gt1681
worms and partial dopaminergic loss was observed in an
additional ,30% of mutant worms after only 24 h (Figure 1A).
The extent of neurodegeneration was further increased 72 h after
intoxication, with ,90% of worms displaying total dopaminergic
Author Summary
Parkinson’s disease (PD) is characterized by the progressive
loss of dopaminergic neurons. While hereditary forms are
known, most cases are attributable to a combination of
genetic and environmental risk factors. In PD models,
dopaminergic neurodegeneration can be triggered by
neurotoxins such as 6-hydroxydopamine (6-OHDA). This
drug, which is taken up by the presynaptic dopamine
reuptake transporter (DAT-1), also causes the selective
death of C. elegans dopaminergic neurons. We found that
TSP-17, a member of the tetraspanin family of membrane
proteins, protects dopaminergic neurons from 6-OHDA-
induced degeneration. We provide evidence that TSP-17
inhibits the C. elegans dopamine transporter DAT-1,
leading to increased neuronal 6-OHDA uptake in tsp-17
mutants. TSP-17 also protects against toxicity conferred by
excessive intracellular dopamine. TSP-17 interacts with the
DOP-2 dopamine receptor, possibly as part of a pathway
that negatively regulates DAT-1. tsp-17 mutants have
subtle behavioral phenotypes that are partly conferred by
aberrant dopamine signaling. In summary, we have used C.
elegans genetics to model key aspects of PD.
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loss at the adult stage (Figure 1A). Enhanced neurodegeneration in
the gt1681 background, albeit to a lesser extent, also occurred in
L2, L3 and L4 larvae treated with 6-OHDA; no such enhance-
ment was seen in adults (Figure 1C). To exclude the possibility
that neurodegeneration might be caused by increased net 6-
OHDA uptake at the organismal level, we took advantage of the
partial growth retardation conferred by 6-OHDA treatment. By
scoring for progression to ensuing developmental stages, we found
the growth of wild-type and gt1681 worms to be similarly retarded
upon toxin treatment, suggesting that gt1681 specifically affects
dopaminergic neurons (Figure 1D).
The gt1681 mutant is recessive in hermaphrodites (Figure 2A).
Genetic linkage was established by single nucleotide polymor-
phism (SNP) mapping, which placed gt1681 on the left arm of the
X chromosome. Using unc-20 and lon-2 genetic markers to
perform three-factor mapping, the locus was further refined to
,10 map units. A cross between an unc-20 gt1681 lon-2 triple
mutant and the CB4856 ‘‘Hawaii’’ mapping strain enabled us to
assess the position of single recombination events relative to
gt1681. This analysis localized gt1681 to an interval between
nucleotides 3,659,480 and 3,737,466 on the physical map. In
parallel, next generation sequencing revealed a single exonic
mutation within this interval, leading to a guanine to adenine
substitution in the C02F12.1 open reading frame and resulting in a
glycine to glutamic acid change at position 109 of the encoded
protein (Figure 2B). C02F12.1 encodes a tetraspanin family,
integral membrane protein called TSP-17 (see below). Rescue of
the phenotype by a fosmid (WRM0626aC02) encompassing tsp-17
and by a tsp-17-encoding transgene (Figure 2C) provides further
evidence that gt1681 confers 6-OHDA hypersensitivity. Hyper-
sensitivity is also conferred by the vc2026 allele, a substitution
obtained via the Million Mutation Project [38] that results in a
glycine to arginine change at position 109 (Figure 2B, 2D). Finally,
two deletion alleles, generously provided by the Japanese
Knockout Consortium, affecting the first exons of tsp-17 also
confer hypersensitivity to 6-OHDA-mediated neurotoxicity (Fig-
ure 2B, 2D) as does the trans-heterozygous gt1681/tm4995
mutant combination (Figure 2A).
Tetraspanins constitute a large protein family, with 30 and 21
members encoded in the human and C. elegans genomes,
respectively [39–41]. Most tetraspanins have not been functionally
characterized. In vertebrates, tetraspanins are suggested to be
involved in cell–cell fusion, cell adhesion, cell motility and tumor
metastasis [42]. In C. elegans, TSP-12 is involved in modulating
Notch signaling, and specific hypodermal TSP-15 expression is
required to mediate covalent tyrosine–tyrosine cross-linking during
cuticle formation [43,44]. C. elegans tsp-17 is predicted to encode
two isoforms. The large isoform, C02F12.1b, encodes a 312 amino
acid protein containing four TM domains. The short isoform,
C02F12.1a, encodes a 243 amino acid protein that, unlike typical
Figure 1. gt1681 mutants are hypersensitive to 6-OHDA. A. The extent of dopaminergic degeneration is indicated for wild-type and gt1681
mutant worms after intoxication with 10 mM 6-OHDA. Neurodegeneration of L1 worms was scored after 24, 48 and 72 h as described in Materials
and Methods, and categorized as ‘‘complete loss,’’ ‘‘partial loss’’ or ‘‘no loss’’ phenotypes (labeled black, white and gray, respectively). Asterisks
represent statistical significance of differences from wild-type (****p,0.00001). B. Representative images showing progressive stages of
dopaminergic neurodegeneration. Absence of degeneration in wild-type (upper left panel) and complete degeneration in gt1681 mutant worms 72 h
post 6-OHDA intoxication (upper right panel, complete degeneration); lower panel and inset are examples of partial degeneration in gt1881. Arrows
indicate ‘blebs in degenerating neurons. C. Extent of neurodegeneration at various developmental stages in wild-type and gt1681 mutant worms
72 h post 6-OHDA intoxication. D. In wild-type and gt1681 worms, development is equally retarded following treatment with 6-OHDA. Progression to
various developmental stages was scored once 95% of untreated worms reached adulthood.
doi:10.1371/journal.pgen.1004767.g001
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tetraspanins, contains only three transmembrane domains and
does not have an intracellular N-terminus. The amino acid change
at position 109 in gt1681 affects a highly conserved residue in the
third transmembrane domain of the long isoform (Figure 2B, 2E).
We confirmed expression of mRNAs encoding for both isoforms,
and verified the predicted intron–exon structure (Figure 2B).
Using BLAST protein analysis of C. elegans TSP-17, we found the
most likely human orthologs of TSP-17 to be CD63, Tspan5 and
CD82 (Figure 2E). A previous phylogenetic analysis placed TSP-
17 within the human CD82 subfamily [45]. However, our
attempts to firmly establish an orthologous relationship between
TSP-17 and a single human tetraspanin or a distinct subfamily of
human tetraspanins were unsuccessful. Our phylogenetic analysis
included all tetraspanins from several nematodes, arthropods,
cnidarians and chordates (Figure S2). We speculate that the rapid
evolution of this protein family, as often occurs with membrane
Figure 2. The TSP-17 tetraspanin family member protects dopaminergic neurons from 6-OHDA. A. Extent of neurodegeneration in
heterozygous and trans-heterozygous worms 72 h post 6-OHDA intoxication. B. Schematic gene model of the two isoforms of tsp-17. Alleles used in
this study are indicated. C. Complementation of tsp-17 expressed under its own promoter (3rd column strain TG2439) and under the dat-1 promoter
(4th column, strain TG2440). Data presented is from scoring the extent of neurodegeneration 72 h post 6-OHDA intoxication. Asterisks represent
statistical significance of differences between tsp-17 and the rescuing lines (****p,0.0001). D. 6-OHDA hypersensitivity conferred by various tsp-17
alleles. E. Alignment of nematode TSP-17 to the most closely related human tetraspanins. Blue bars indicate transmembrane domains and brown bars
designate extracellular loops (EC1 and EC2). The arrow indicates amino acid G109, which is mutated in the C. elegans gt1681 and vc2026 mutants. The
red box indicates the CCG motif in the EC2, which is highly conserved throughout the tetraspanin protein family. Hs, Homo sapiens; Ce,
Caenorhabditis elegans; Cbn, C. brenneri; Cre, C. remanei; Cbr, C. briggsae.
doi:10.1371/journal.pgen.1004767.g002
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proteins, compromised our ability to firmly identify a human
ortholog of C. elegans TSP-17.
To assess the TSP-17 expression pattern, we used biolistic
bombardment to generate transgenic worms (TG2439) express-
ing a tsp-17::GFP gene fusion (NM001) under the control of its
own promoter and 39UTR. A dat-1 (promoter)::mCherry fusion
(PBI001) was co-bombarded to mark dopaminergic neurons.
The tsp-17::GFP gene fusion largely suppressed the hypersen-
sitivity phenotype conferred by tsp-17, thus confirming its
functionality (Figure 2C, bar 3). Importantly, fusion protein
expression was observed in all dopaminergic neurons: it was
uniform along axons and dendrites of both dorsal and ventral
pairs of CEP neurons, as well as in ADE neurons (Figure 3A–I,
arrows indicate axons and dendrites) and in the posterior PDE
neurons. Within the cell body, the TSP-17::GFP fusion seems to
be excluded from the nucleus, a pattern that is more evident in a
‘‘close-up’’ image of a PDE neuron, where the signal appears to
form a ring-like structure around the nucleus (Figure 3J–L
arrowheads). mCherry aggregates (which are not linked to
neurodegeneration) form dot-like structures in dendrites and
axons (arrows), and the surrounding TSP-17 fluorescent signal
suggests plasma membrane expression (arrow, Figure 3K). TSP-
17 enrichment at the plasma membrane can be observed most
prominently in the large cells of the vulva and the sheath cells
enclosing the spermatheca (Figure 3M, N). In the spermatheca,
TSP-17::GFP expression is also clearly enriched around the
nucleus (Figure 3N, arrowheads), possibly localizing to the
nuclear membrane or endoplasmic reticulum (Figure 3N,
arrowhead). Analysis of subcellular localization in the vulva
and spermatheca revealed that the TSP-17::GFP (gt1681)
mutant protein is uniformly expressed in the cytoplasm, with a
loss of enrichment at the plasma membrane and around the
nucleus (Figure S3A). Thus, the gt1681 mutation, which leads
to an amino acid change in the fourth transmembrane domain,
might compromise the membrane localization of TSP-17 and
therefore block its function. TSP-17::GFP is also expressed in
multiple neurons throughout worm development. For instance,
the NSM serotonergic neuron, which is characterized by
extensive axon sprouting, shows TSP-17::GFP expression along
its entire length (Figure 3O). Prominent expression was also
observed in the muscles of early stage larvae (Figure 3P). Finally
expression also appears to be apparent in muscles of the adult
head (Figure 3B, C, H, I). In summary, the TSP-17::GFP
expression indicates that TSP-17 is expressed in dopaminergic
neurons. Transgene expression in dopaminergic neurons was
also confirmed by analyzing a TSP-17::GFP expressing trans-
genic strain crossed to a DAT-1 reporter strain (Figure S3B). We
cannot rule out expression of TSP-17 not uncovered by the
transgene, due to missing regulatory sequences. We next wanted
to investigate whether TSP-17 expression in dopaminergic
neurons protects them from 6-OHDA-mediated neurodegener-
ation. By direct injection of transgenes into the gonad, we
generated transgenic worms overexpressing TSP-17 under the
control of the dat-1 promoter. Consistent with TSP-17
expression in dopaminergic neurons, we found partial rescue
of the hypersensitivity conferred by gt1681 (Figure 2C, com-
pare bars 1, 2 and 4). Interestingly, overexpression of TSP-17
and TSP-17 (gt1681) under the dat-1 promoter led to
spontaneous neurodegeneration (Figure S4A, B, respectively).
This phenotype tended to be more severe following TSP-17
(gt1681) overexpression. Taken together, these data indicate
that TSP-17 indeed functions in dopaminergic neurons, and
that excessive TSP-17, especially the mutant form, leads to
spontaneous neurodegeneration.
We next wished to address how TSP-17 protects dopaminergic
neurons. We hypothesized that TSP-17 might affect dopamine
synthesis, or dopamine and 6-OHDA uptake or degradation.
Dopamine metabolism is itself a source of oxidative stress and may
initiate ROS-mediated injury to dopaminergic neurons. The link
between excessive dopamine exposure and toxicity is controversial,
but overexpression of CAT-2, the rate-limiting enzyme in
dopamine synthesis in C. elegans, is reported to lead to age-
dependent degeneration of dopaminergic neurons [46]. We
repeated these experiments, and indeed found that neurodegen-
eration conferred by CAT-2 overexpression in dopaminergic
neurons is enhanced in the gt1681 mutant background (Fig-
ure 4A). In contrast, we found CAT-2 overexpression to confer a
strong resistance toward 6-OHDA-dependent neurodegeneration
in both wild-type and gt1618 backgrounds (Figure 4B). We
consider it likely that 6-OHDA resistance conferred by CAT-2
overexpression can be explained by reduced 6-OHDA uptake into
dopaminergic neurons in the presence of excessive levels of
intracellular dopamine. Our results indicate that tsp-17 protects
against 6-OHDA toxicity and toxicity caused by excessive
dopamine.
Since these genetic interactions suggest that dopamine levels
could be altered in tsp-17mutants, we next investigated behavioral
phenotypes associated with dopamine. Dopamine synthesis and
release are required for the basal slowing response, in which
worms reduce their speed when encountering a bacterial lawn
[36]. We did not observe a defect in this response, indicating that
both dopamine synthesis and extracellular dopamine sensing by
receptors are intact in tsp-17 mutants (Figure S5A). One of the
most accessible phenotypes thought to be associated with excessive
extracellular dopamine is the SWIP (Swimming Induced Paralysis)
phenotype [37]. While wild-type worms placed into a drop of
water maintain their thrashing frequency dat-1 mutants become
progressively paralyzed. The SWIP phenotype is ascribed to
excessive extracellular dopamine as a consequence of the reuptake
defect in the dat-1 mutant. Excessive extracellular dopamine
triggers paralysis by hyperactivating the DOP-3 receptor ex-
pressed on cholinergic neurons and hence blocking acetylcholine
release [33]. To perform this experiment, we placed L4 worms
into drops of water and scored their ability to swim over a period
of 30 minutes. As expected, we found that wild-type but not dat-1
mutant worms can swim for 30 minutes with no change in the
speed or pattern of swimming. All four tsp-17 mutants showed a
partial SWIP phenotype (Figure 5A). This phenotype is probably
caused by dopaminergic signaling because it can be rescued by
deletion of the dop-3 dopamine receptor and by deletion of the
cat-2 tyrosine hydroxylase (Figure 5A and Figure 5B). It was
surprising to find a SWIP phenotype in tsp-17 mutants as we
argue that tsp-17 inhibits dat-1 function (see below). While
elucidating the exact mechanism of how TSP-17 affects behavioral
phenotypes will require further investigation we speculate that
hyper-activation of DAT-1 in tsp-17 strains could trigger a
feedback loop that transiently enhance extracellular dopamine
levels inducing the weak SWIP phenotype we observe.
We also tested for a SWIP phenotype in L1 stage worms, and
found that all tsp-17 mutants tested, except the gt1681 allele,
behaved similarly to dat-1 mutants (Figure 5C, D). This pheno-
type, however, is not suppressed by a dop-3 mutation or blocked
by a cat-2 mutation (Figure 5D and Figure S5B). We discovered
that the ‘‘L1 SWIP phenotype’’ is linked to lethality because
worms placed onto agar plates after SWIP assay show reduced
viability (Figure S5C, D). Thus, the L1 ‘‘swimming-induced
lethality’’ phenotype is unlikely to be related to dopamine levels.
Given that TSP-17 is expressed in body wall muscles in L1 larvae,
Neuroprotection by the TSP-17 Tetraspanin in C. elegans
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we speculate that swimming-induced lethality might be caused by
a muscle defect.
To systematically test whether TSP-17 protects dopaminergic
neurons by modulating dopamine metabolism, catabolism, reup-
take or signaling, we performed a genetic epistasis analysis. As
expected, tsp-17 dat-1 double mutants were completely resistant to
6-OHDA-induced neurodegeneration, consistent with the notion
that TSP-17 does not bypass 6-OHDA uptake by the DAT-1
dopamine transporter (Figure 6A). We observed no alterations in
6-OHDA sensitivity in cat-2 (tyrosine hydroxylase), bas-1
(aromatic amino acid decarboxylase/AAADC) and cat-1 (VMAT
ortholog required for dopamine packaging) tsp-17 double mutants,
indicating that TSP-17 is unlikely to affect levels of dopamine
synthesis or packaging (Figure S6).
As 6-OHDA can enter dopaminergic neurons through the
DAT-1 transporter owing to its structural similarity to dopamine
[3,47], we wondered whether DAT-1 localization or activity is
modified in a tsp-17 mutant background. Having established that
6-OHDA hypersensitivity in tsp-17 worms depends on the DAT-1
transporter (Figure 6A), we tested the hypothesis that enhanced
DAT-1 transporter activity may contribute to enhanced 6-
OHDA-mediated neurotoxicity. Using a functional pdat-1::dat-
1::YFP translational fusion, we found that overexpression of this
transgene generated by bombardment does not confer overt 6-
OHDA hypersensitivity (Figure 6A, Figure S7). Furthermore, the
localization of DAT-1::YFP was similar between wild-type and tsp-
17 mutants worms (Figure S8A), a notion further confirmed by
Structural Illumination ‘super resolution’ images of CEP dendrites
(Figure S8B). Additionally, photobleaching experiments indicated
that ,half of DAT-1::YFP is in the mobile fraction and that the
t1/2 is around 30 seconds in both wild-type and tsp-17(gt1681)
worms (Figure S8C–E). We thus aimed to test whether TSP-17
Figure 3. TSP-17::GFP expression. Analysis of the TG2439 strain containing dopaminergic neurons labeled by mCherry and tsp-17 C-terminally
fused to GFP and driven by its own promoter. A, D, G, J. Dopaminergic neurons expressing the mCherry marker. Neurons are indicated. White arrows
highlight dendrites and axons. B, E. H, K. Expression of TSP-17::GFP. C, F, I, L. Merged images. White arrows highlight dendrites and axons. K, L, N.
The arrow-heads indicate TSP-17::GFP signal enrichment around the nucleus. Expression in the vulva (M), the spermatheca (N), a NSM neuron (O),
and in body wall muscle cells (P).
doi:10.1371/journal.pgen.1004767.g003
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negatively regulates DAT-1 activity using a pharmacological
approach. We confirmed previous reports that imipramine
specifically inhibits the DAT-1 transporter in the worm [3]
(Figure 6B, left panels, wild-type 0.25 mM and 1 mM). We
reasoned that if DAT-1 is hyperactive in tsp-17 (gt1681),
relatively more imipramine should be needed to inhibit DAT-1
activity and prevent neurodegeneration. We thus treated wild-
type, tsp-17 (gt1681) worms and wild-type worms overexpress-
ing DAT-1::YFP with 10 mM 6-OHDA and increasing doses of
imipramine (Figure 6B, middle and right panels). We indeed
found that higher levels of imipramine are needed to reduce
neurodegeneration in DAT-1::YFP overexpressing worms and
in tsp-17 (gt1681) worms, and that the effect being stronger in
the tsp-17 (gt1681) mutant. Reduced levels of neurodegener-
ation levels were most clearly observed when concentrations of
0.125 mM and 0.25 mM imipramine were used (Figure 6B).
This result provides evidence that DAT-1 activity may be higher
in the tsp-17 mutant background. We aimed to provide further
Figure 4. tsp-17 (gt1681) enhances the neurodegeneration phenotype of cat-2-overexpressing lines, and cat-2 overexpression
protects against 6-OHDA toxicity. A. cat-2 induced neurodegeneration. Analysis of cat-2-overexpressing stains UA57 baIn4 [pdat-1::gfp pdat-
1::cat-2] and TG2402 baIn4[pdat-1::gfp pdat-1::cat-2]; tsp-17(gt1681). Error bars represent standard deviation. Asterisks represent statistical difference
between cat-2::gfp adults on days 5 and 7 (**p,0.005). B. cat-2 overexpression suppresses 6-OHDA-induced neurotoxicity. Experiments were done in
triplicate and the average is shown. Data presented is from scoring the extent of neurodegeneration 72 h post 6-OHDA intoxication.
doi:10.1371/journal.pgen.1004767.g004
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support for this hypothesis by directly measuring dopamine
uptake, following previously described procedures. We macer-
ated C. elegans embryos to establish primary embryonic cell
cultures, and used these for dopamine uptake assays [48,49].
Using two concentrations of tritiated dopamine, we indeed
found increased dopamine uptake in tsp-17 mutants (Figure 6C,
D). We note that we found this in 7/8 repeat experiments.
However, we also note that only a very small proportion of
tissue culture cells are dopaminergic neurons and that the
absolute amount of dopamine uptake is low especially in the
wild-type background.
Our combined genetic, pharmacological and biochemical
analysis suggests that TSP-17 modulates DAT-1 activity. Previous
studies using tissue culture-based assays demonstrated that
dopamine receptor activation might promote DAT-1 activity
[25,50,51]. Consistent with these results, we found dop-2 and dop-
3 mutant worms to be partially resistant to high doses of 6-OHDA
compared to wild-type (Figure 7A). We therefore investigated
whether tsp-17 genetically interacts with dopamine receptors to
modify DAT-1 activity and confer differential 6-OHDA sensitiv-
ity. This was done by assessing the sensitivity of tsp-17 mutants in
the absence of the C. elegans DOP-1 D1-like receptor and/or in
the absence of the DOP-2 and/or DOP-3 D2-like receptors. C.
elegans DOP-1 is expressed in a variety of cells, including
cholinergic neurons, mechanosensory neurons, head muscles and
neuronal support cells. DOP-3 is expressed postsynaptically and its
antagonism of DOP-1 in cholinergic neurons is required for the
regulation of locomotion [33]. The DOP-2 receptor is expressed
both postsynaptically and presynaptically. When expressed pre-
synaptically, it acts as an autoreceptor on the plasma membrane of
dopaminergic neurons. We found that dop-1; tsp-17 (gt1681) was
as sensitive to 6-OHDA as the respective tsp-17 single mutant. In
contrast, 6-OHDA hypersensitivity was reduced in dop-2; tsp-17
(gt1681) and dop-2; tsp-17 (tm4994) and in dop-3; tsp-17
(gt1681) and dop-3; tsp-17 (tm4994) double mutant worms
(Figure 7B, C and Figure S9) Our genetic data thus argue that
TSP-17 might inhibit DOP-2 and DOP-3 function, which in turn
might be required for full DAT-1 transporter activity (Figure 7A,
E). Given that deletion of dop-2 and dop-3 only partially rescues 6-
OHDA hypersensitivity in tsp-17 mutants, we speculate that TSP-
17 also inhibits DAT-1 activity independently of DOP-2 and
DOP-3.
Figure 5. Behavioral phenotypes associated with tsp-17 mutants. A. Quantitative analysis of SWIP behavior at L4-stage, over 30 minutes. B.
The SWIP phenotype of tsp-17(tm4995) in L4-stage worms is rescued by dop-3 deletion. C. Quantitative analysis of SWIP behavior in L1-stage worms
over 20 min. D. The SWIP phenotype of tsp-17(tm4995) at L1 stage is not rescued by dop-3 deletion. Assays were done in triplicate for the total
number of worms indicated by N values. Error bars represent the standard error of the mean. Asterisks represent statistically significant differences
from the wild-type (***p,0.01). To facilitate comparison, strains are indicated by the same color code.
doi:10.1371/journal.pgen.1004767.g005
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We next aimed to investigate how TSP-17 might regulate
DAT-1 or D2-like receptors to modulate DAT-1 activity. Given
that these are integral membrane proteins, we employed the split-
ubiquitin membrane-based yeast two-hybrid system [52]. In this
system, a C-terminal ubiquitin moiety fused to a transmembrane
protein and a transcription factor is used a bait. An N-terminal
ubiquitin moiety is used as the ‘‘prey.’’ Upon ‘‘reconstruction’’ of
the split ubiquitin, this molecule is recognized by a protease,
which cleaves the transcription factor, thus promoting reporter
gene activation. By employing various bait and prey fusions with
TSP-17, DAT-1 and DOP-2, we could not find a direct
interaction between TSP-17 and DAT-1 using the split-ubiquitin
system (Figure 7D). In contrast, we found that DOP-2 and TSP-
17 may indeed interact. The specificity of this interaction was
clearly revealed when the beta-galactosidase reporter assay was
used as an output. In addition, yeast colony formation on his-3 or
his-3 ade-2 plates was enhanced when the corresponding
reporters where used (Figure 7D). Thus, TSP-17 might modulate
DOP-2 activity by a direct physical interaction, consistent with
TSP-17 affecting ligand binding, downstream signaling or
membrane trafficking of DOP-2-like receptors. Our genetic data
also suggest that TSP-17 might also act via other factors to
dampen DAT-1 activity (Figure 7B).
Discussion
Using C. elegans as a model and employing unbiased genetic
approaches, we aimed to find neuroprotective genes that alleviate
the 6-OHDA-induced degeneration of dopaminergic neurons.
Based on our genetic data, which is supported by the character-
ization of several alleles and transgenic rescue experiments, we
provide compelling evidence that TSP-17 protects dopaminergic
neurons from 6-OHDA-mediated toxicity. TSP-17 appears to
function in dopaminergic neurons, and our combined genetic,
pharmacological and biochemical evidence suggests that it might
act by antagonizing DAT-1 dopamine transporter activity. We do
not know how TSP-17 regulates DAT-1 at a mechanistic level.
TSP-17 is a member of the evolutionarily conserved family of
tetraspanins, comprising 20–50 kDa membrane proteins that
contain four transmembrane domains. A characteristic feature of
tetraspanins is their ability to form lateral associations with each
other and with other proteins. Such interactions are thought to
Figure 6. Evidence for DAT-1 hyperactivation in tsp-17 worms. A. dat-1::yfp transgenic worms (TG2470) do not exhibit hypersensitivity to
10 mM 6-OHDA. The extent of neurodegeneration was scored 72 h post 6-OHDA intoxication. Asterisks represent statistically significant differences
compared to tsp-17 worms (****p,0.00001) B. More imipramine than in wild-type worms is needed to prevent neurodegeneration in tsp-17 mutants
and in dat-1::yfp overexpression worms co-treated with 50 mM 6-OHDA. Data presented is from scoring the extent of neurodegeneration 72 h post 6-
OHDA intoxication. The imipramine concentration is indicated on the x axis. N, total number of worms from each strain examined for every treatment.
Error bars represent the standard error of the mean. Asterisks (below top bar) represent statistically significant differences compared to wild-type;
worms treated with 0.125 mM imipramine are compared (****p,0.00001). Lower bars indicate difference within individual strains (no imipramine
compared to 0.125 mM imipramine; *p,0.05, *p,0.005, ****p,0.00001) C., D. [3H]-dopamine (DA) uptake in wild-type and tsp-17 worms. Uptake
assays were performed using 50 nM (C) and 250 nM [3H]-DA (D).
doi:10.1371/journal.pgen.1004767.g006
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lead to a dynamic assembly, resulting in the formation of a
network of molecular interactions referred to as the tetraspanin
web [41,53]. Tetraspanins are thought to have regulatory
functions in the ligand binding, downstream signaling, protein
trafficking and proteolytic activities of associated proteins [42,54].
In C. elegans, only two tetraspanins have known functions. TSP-
15 appears to be required to activate the BLI-3 dual oxidase to
regulate H202 production at the plasma membrane and thus alter
dityrosine cross-linkage of extracellular matrix proteins [44,55].
Genetic evidence suggests that TSP-12, most closely related to
human TSPAN33, appears to facilitate Notch signaling redun-
dantly with TSP-14. Thus conserved tetraspanins likely function
by facilitating c-secretase cleavage of the membrane-bound form
of Notch, thus promoting nuclear localization of this transcription
factor [43].
DAT-1 hyperactivity in the tsp-17 mutants could result from
altered DAT-1 localization or abundance at the cell membrane;
alternatively, TSP-17 might indirectly regulate DAT-1 activity.
Using a functional DAT-1::YFP construct, we did not see any
obvious change in DAT-1 expression, localization, or change in
half life in tsp-17 mutants and we thus favor the idea that TSP-17
regulates DAT-1 activity. Our finding that TSP-17 genetically and
biochemically interacts with the DOP-2 D2-like dopamine
receptor, suggests an indirect mode of DAT-1 regulation by
TSP-17 (Figure 7E). Our genetic analysis provides evidence that
TSP-17 might in part regulate DAT-1 via DOP-2 and DOP-3
dopamine receptors (Figure 7E). We found that depletion of the
D2-like dopamine receptors, DOP-2 and/or DOP-3, in tsp-17
mutants leads to a moderate reduction in the 6-OHDA
hypersensitivity conferred by tsp-17, while D2-like dopamine
receptor single knockout strains show the same 6-OHDA
sensitivity as wild-type worms. Thus, our analysis suggests that
tsp-17 genetically interacts with D2-like dopamine receptors, in
line with our observation that TSP-17 directly binds to DOP-2. In
mammalian systems, dopamine autoreceptors are reported to have
a major role in providing inhibitory feedback to adjust the rate of
Figure 7. Dopamine receptors act antagonistically to modulate the sensitivity of tsp-17 (gt1681) mutants to 6-OHDA. Worms of the
indicated genotypes were intoxicated with A. 50 mM, B. 10 mM 6-OHDA and C. 5 mM 6-OHDA and scored for neurodegeneration 72 h post
intoxication. Experiments were done in triplicate and the average data is presented. N, total number of animals examined for each strain. Error bars
represent the standard error of the mean. Asterisks represent statistically significant differences (***p,0.0001, ****p,0.00001). D. Evidence for a
direct interaction between DOP-2 and TSP-17. Growth on -Leu, -Trp, -His (left panel) and -Leu, -Trp, -His, -Ade (middle panel) plates is shown. The right
panel depicts a b-galactosidase assay. E. Working model as to how TSP-17 might interact with DAT-1 and DOP-2 to modulate level of DAT-1 activity.
Arrows indicate activation. T-bars indicate repression. The question mark indicates that we do not know the mechanism of DAT-1 inhibition by TSP-
17.
doi:10.1371/journal.pgen.1004767.g007
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neuronal firing, dopamine synthesis and dopamine release in
response to the dopamine level in the synaptic cleft [30,32].
Several studies suggest that vertebrate D2 dopamine receptors also
modulate DAT-1 activity to regulate the dopamine level in the
synaptic cleft. Cass and Gerhardt used pharmacological approach-
es to demonstrate that inhibition of D2 class dopamine receptors
significantly inhibits DAT function [50]. Two independent studies
provided evidence that D2 receptors regulate both the activity and
cell surface expression of DAT-1 [25,51]. Nevertheless, further
investigations are required to establish functional links between C.
elegans DOP-2 receptors and DAT-1 activity. The ability of TSP-
17 to inhibit DAT-1 both via DOP-2 and independent of D2-like
receptors (Figure 7E) suggests that TSP-17 modulates the activity
of multiple signaling proteins. Indeed, our observation of excessive
neurodegeneration following wild-type, and especially mutant,
TSP-17 overexpression in dopaminergic neurons hints that
malfunctioning and/or excessive TSP-17 blocks pathways needed
to maintain the integrity of dopaminergic neurons. The enhanced
defect associated with overexpression of mutant TSP-17 that fails
to show the correct cytoplasmic localization hints the neurotoxicity
might be conferred by the sequestration of TSP-17 interacting
proteins essential for neuronal survival.
Dopamine neuronal dysfunction has been associated with
several common neurobehavioral disorders, including drug
addiction, schizophrenia and attention-deficit hyperactivity disor-
der [32,56–58]. The DAT-1 dopamine transporter plays a central
role in dopamine signaling, and it is likely to be subjected to
complex modes of regulation. DAT-1 is the target of psychoactive
addictive drugs such as cocaine and amphetamine, and DAT1
overexpression leads to increased amphetamine sensitivity [59–
63]. Mechanisms related to dopamine signaling tend to be
evolutionarily conserved. Thus, studies aimed to genetically define
modulators of dopamine signaling and 6-OHDA-mediated toxicity
will provide important insights into the mechanisms of dopamine
signaling in health and disease.
Idiopathic PD is thought to be triggered by a combination of
environmental factors and genetic susceptibility, and a case has
been made that exposure to environmental toxins such as the
pesticides paraquat and rotenone leads to increased PD [9].
Indeed, chemical and tissue culture studies have provided evidence
that increased dopamine levels may lead to enhanced neurode-
generation, probably through the generation of toxic intermediates
such as the neurotoxic product of dopamine oxidation, 6-OHDA
[13,15,64–68]. The specificity of 6-OHDA entry into dopamine
neurons depends on DAT, and DAT antagonists can block uptake
[3,4,11,47]. Interestingly, DAT-1 hyperactivity in tsp-17 mutants
further enhances the neurodegeneration conferred by elevated
dopamine synthesis in CAT2 tyrosine hydroxylase-overexpressing
worm strains. Thus, DAT-1 hyperactivity might enhance neuro-
degeneration by further increasing the intracellular concentration
of dopamine and/or toxic metabolites. DAT1 expression or
activity has not been linked to PD, but it is intriguing that among
dopamine neurons those residing in the substantia nigra express
the highest DAT levels in vivo and are most strongly affected in
PD [4,60].
Materials and Methods
C. elegans strains and maintenance
Strains were grown at 20uC under standard conditions, unless
indicated otherwise. N2 Bristol was used as the wild-type strain.
The tsp-17(tm4994) and tsp-17(tm5169) mutants were generated
and kindly provided by Shohei Mitani of the National Bioresource
Project for the Nematode (http://www.shigen.nig.ac.jp/c.
elegans/). Details of the respective alleles are described by the
National Bioresource Project for the Nematode and by WormBase
(www.wormbase.org). All mutants were outcrossed a minimum of
four times to the TG2435 vtIs1[pdat-1::gfp] strain originally
generated by the Blakely laboratory (BY200) and repeatedly
crossed into the N2 background.
Strains
TG2435 vtIs1[pdat-1::gfp; rol-6] V,
TG1681 vtIs1 V; tsp-17(gt1681) X,
TG2436 vtIs1 V; tsp-17(tm4994) X,
TG2437 vtIs1 V; tsp-17(tm5169) X,
TG2438 vtIs1 V; tsp-17(gk276386) X,
TG2462 vtIs1 V; CB4856,
TG2463 vtIs1 V; lon-2(e678) unc-20(e112) X,
TG2464 vtIs1 V; tsp-17(gt1681) unc-20(e112) X,
TG2465 vtIs1 V; tsp-17(gt1681) lon-2(e678) X,
TG2395 cat-2(e1112) II; vtIs1 V,
TG2394 cat-2(e1112) II; vtIs1 V; tsp-17(gt1681) X,
TG2396 bas-1(tm351) III; vtIs1 V,
TG2397 bas-1(tm351) III; vtIs1 V; tsp-17(gt1681) X,
TG2399 vtIs1 V; cat-1(e1111) X,
TG2398 vtIs1 V; cat-1(e1111) tsp-17(gt1681) X,
TG2400 dat-1(ok157) III; vtIs1 V,
TG2401 dat-1(ok157) III; vtIs1 V; tsp-17(gt1681) X,
TG2404 amx-1(ok659) III; vtIs1 V,
TG2403 amx-1(ok659) III; vtIs1 V; tsp-17(gt1681) X,
TG2406 amx-2(ok1235) I; vtIs1 V,
TG2405 amx-2(ok1235) I; vtIs1 V; tsp-17(gt1681) X,
TG2408 amx-2(ok1235) I; amx-1(ok659) III; vtIs1 V,
TG2407amx-2(ok1235) I; amx-1(ok659) III; vtIs1 V; tsp-
17(gt1681) X,
TG2410 vtIs1 V; dop-1(vs100) X,
TG2409 vtIs1 V; dop-1(vs100) tsp-17(gt1681) X,
TG2412 vtIs1 dop-2(vs105) V,
TG2411 vtIs1 dop-2(vs105) V; tsp-17(gt1681) X,
TG2414 vtIs1 V; dop-3(vs106) X,
TG2413 vtIs1 V; dop-3(vs106) tsp-17(gt1681) X,
TG2466 vtIs1 dop-2(vs105) V; dop-3(vs106) X,
TG2467 vtIs1 dop-2(vs105)V; dop-3(vs106) tsp-17(gt1681)X,
TG2415 vtIs1 dop-2(vs105) V; dop-1(vs100) dop-3(vs106) X,
TG2416 vtIs1 dop-2(vs105) V; dop-1(vs100) dop-3(vs106)
tsp-17(gt1681) X,
UA57 baIn4[pdat-1::gfp pdat-1::cat-2],
TG2402 baIn4[pdat-1::gfp pdat-1::cat-2],; tsp-17 (gt1681) X,
TG2470 gtIn2469[pdat-1::dat-1::yfp::let-858 39UTR, unc-
119(+)]; gtIn2468[pdat-1::mcherry::let858 39UTR, unc-
119(+)]; unc-119(ed3) III,
TG2471 gtIn2469[pdat-1::dat-1::yfp::let-858 39UTR, unc-
119(+)]; gtIn2468[pdat-1::mcherry::let858 39UTR, unc-
119(+)]; unc-119(ed3) III; tsp-17(gt1681) X,
TG2439 gtIn2439[ptsp-17::tsp-17::gfp::tsp-17 39UTR, pdat-
1::mcherry::let858 39UTR, unc-119(+)]; unc-119(ed3) III,
TG2472 tsp-17(gt1681) X; gtIn2439[ptsp-17::tsp-17::gfp::tsp-
17 39UTR, pdat-1::mcherry::let858 39UTR, unc-119(+)]; unc-
119(ed3) III,
TG2440 gtEx2440[pdat-1::tsp-17::cfp:: let-858 39UTR, unc-
119(+)]; unc-119(ed3) III; vtIs1 [pdat-1::gfp; rol-6] V,
TG2473 vtIs1 [pdat-1::gfp; rol-6] V; tsp-17(gt1681) X;
gtEx2440 [pdat-1::tsp-17::cfp:: let-858 39 UTR, unc-119(+)],
TG2474 vtIs1 [pdat-1::gfp; rol-6] V; unc-119(ed3) III;
gtEx2474[pdat-1::tsp-17(G74E)::cfp:: let-858 39UTR, unc-
119(+)],
TG2478 cat-2(e1112) II; vtIs1V; tsp-17(tm4994) X,
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TG2475 dat-1(ok157) III; vtIs1V; tsp-17(tm4995) X,
TG2477 vtIs1; dop-3(vs106) tsp-17(tm4995) X,
TG2476 dat-1(ok157) III; vtIs1V; dop-3(vs106) X,
Generation of transgenic worms and constructs. NM001,
NM002, Pb1001, PbI002, PbI003 and AH001 plasmid sequences
can be obtained upon request.






































The TG2470 and TG2439 strains were generated by biolistic
bombardment of unc-119(ed3) worms with AH001 and NM001
plasmids, respectively. The TG2440 and TG2474 strains were
generated by microinjections of unc-119 (ed3) mutants.
Mutagenesis and mapping
EMS was added to 4 ml synchronized young adult worms in
M9 buffer to a final concentration of 25 mM and incubated for
4 h at 20uC. Mutagenized worms were washed in M9 buffer and
incubated at 15uC. Synchronous F1-generation L1 larvae were
used for screening. F2-generation L1 larvae from mutagenized
TG2435 dat-1::gfp (BY200) worms were used for the mutagenesis
screen. L1 larvae were intoxicated with 10 mM 6-OHDA. After
72 h, worms with the highest incidence of neurodegeneration were
isolated and scored as hypersensitive. SNP mapping of mutants
was done as previously described [69].
Drug treatment of worms
To obtain synchronized L1 larvae, 1–10 adult worms (24 h
post-L4 stage) were incubated in 70 ml M9 without food on at
20uC, with shaking at 500 rpm for 27–40 h to lay eggs. After
hatching, all L1 larvae were collected. Approximately 50 L1 larvae
were added to an assay mix (50 ml) containing 10 mM 6-OHDA
and 40 mM ascorbic acid, and incubated for 1 h at 20uC, with
shaking at 500 rpm. For co-treatment with imipramine or
haloperidol, the respective compounds were added to the assay
mix at the same time as 6-OHDA. After a 1-h incubation, M9
buffer (100 ml) was added to the assay mix, and the solution
containing L1 worms was then transferred to an unseeded NGM
plate. After 30 min, L1 worms were individually picked and
transferred onto a fresh NGM plate seeded with a line of OP50
bacteria to ease subsequent scoring. Intoxicated worms were
incubated at 20uC and scored for dopaminergic neurodegenera-
tion every 24 h for 3 days. All 6-OHDA treatments were done in
triplicate and at least 80–100 worms were tested for each strain
and condition.
Swimming-induced paralysis assay
All worms used for SWIP analysis were grown on NGM plates
seeded with E. coli OP50 bacteria. For each test, 5–10 L4
hermaphrodites or 10 L1 worms were placed into 40 ml water in a
single well of a Pyrex Spot Plate. Paralyzed worms were counted at
1-min intervals using a Leica dissecting microscope [70]. L1
worms were hand picked from seeded plates, 12 hours after the
addition of embryos, obtained by bleaching.
Scoring neuronal degeneration and image acquisition
For semi-quantitative analyses of 6-OHDA-induced degenera-
tion, worms were examined using a Leica fluorescent dissecting
microscope. The absence of all eight dopaminergic neurons in
worms was scored as ‘‘complete loss.’’ The presence of a complete,
intact set of eight dopaminergic neurons was scored as ‘‘no loss.’’
Any intermediate situation, for example a damaged or absent
subset of dopaminergic neurons or missing dendrite portions, was
scored as a ‘‘partial loss.’’ Neurodegeneration resulting from cat-2
overexpression was scored using developmentally synchronized
worms, as indicated. A DeltaVision microscope (Applied Precision)
was used to acquire images. All images were analyzed using
softWoRx Suite and softWoRx Explorer software (Applied
Precision).
DNA constructs for the split-ubiquitin system
Total RNA was isolated and reverse transcribed from wild-type
C. elegans (N2) using an RNeasy mini kit (QIAGEN). Coding
regions of dop-2c (K09G1.4c) and dat-1 (T23G5.5) were amplified
and cloned into pBT3-STE vectors (Dual Systems Schlieren) for
expression of a fusion protein containing the C-terminal half of
ubiquitin (Cub) and the artificial transcription factor LexA-VP16.
tsp-17b (C02F12.1b) cDNA was amplified and cloned into prey
vector pPR3-STE for expression of a fusion protein containing a
mutated version of the N-terminal half of ubiquitin (NubG).
Constructs were verified by DNA sequencing, and sequences of
the respective constructs can be provided upon request. Yeast
transformations and pairwise interaction assays were done
according to the protocol of Dualsystems Schlieren.
C. elegans cell culture and DAT-1 uptake assay
Embryonic cells were prepared as described previously
(Christensen, M, et al 2002, Neuron). The uptake assay was done
according to Carvelli et al. (2004). Briefly, C. elegans cells cultured
for 2 days were washed twice with KRH buffer (120 mM NaCl,
4.7 mM KCl, 1.2 mM KH2P04, 10 mM Hepes, 2.2 CaC12,
10 mM glucose, 0.1 mM ascorbic acid and 0.1 mM tropolone and
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0.1 mM pargyline mono amine oxidase inhibitors) and incubated
with 50 or 250 nM [3H]-dopamine for 20 min at room
temperature. Uptake was terminated by three washes of ice-cold
KRH buffer, and cells were lysed by incubation with 1% SDS for
20 min. [3H]-dopamine uptake was measured in each genetic
background, based on radioactive counts, using a scintillation
counter (PerkinElmer Liquid Scintillation Analyzer Tri-Carb
1800TR). Total cell numbers were determined with a hemocy-
tometer and were used to normalize radioactive counts. Cell
numbers varied between experiments but were not biased towards
mutant or control strain: There were 400,000/400,000, 75,000/
150,000 and 1,000,000/400,000 cells for control/mutant strain,
respectively. Cell extraction and uptake assays were always done
simultaneously for both strains. The error bars depict the standard
error of the means (SEM).
Statistical analysis
Neurodegeneration and SWIP assay data are presented as the
average of three biological replicates, and error bars represent the
standard error of the mean, unless otherwise indicated. When
assaying neurodegeneration statistical significance was calculated
using the Chi-Sqare test using Yates p-values. http://www.
quantpsy.org/chisq/chisq.htm. The statistical significance of
differences in the SWIP assays (Figure 5) was calculated using
the two-tailed t-test.
Supporting Information
Figure S1 Neurodegeneration induced by various doses
of 6-OHDA, scored 72 h post intoxication.
(TIF)
Figure S2 Phylogenetic analysis of TSP-17. For phyloge-
netic analysis, sequences were aligned by ClustalW using Jalview
software and an un-rooted phylogenetic tree was generated using
SplitsTree. Bootstrap values at the center of the tree (magnified in
the red box) indicate divergence. Abbreviations are as follows. As,
Ascaris suum; Hm, Hydra magnipapillata; Ix, Ixodes scapularis;
Pp, Pristionchus pacificus; Hs, Homo sapiens; Nv, Nematostella
vectensis; Dm, Drosophila melanogaster; Bm, Brugia malai; Ci,
Ciona intestinalis; Ce, Caenorhabditis elegans; Cbn, Caenorhabdi-
tis brenneri; Cre, Caenorhabditis remanei; Cbr, Caenorhabditis
briggsae. C. elegans TSP-17 is highlighted by a red box.
(TIF)
Figure S3 A. TSP-17(GT1681)::GFP expression in the
vulva (left panel) and the spermatheca (right panel).
Strain TG2474 was used. Images are projections of six Z-stacks.
B. TSP-17 expression in ADE and CEP cell bodies.
(TIF)
Figure S4 TSP-17 overexpression in a wild-type back-
ground induces neurodegeneration without 6-OHDA
treatment. Strains used were (A) TG2440 for TSP-17 overex-
pression and (B) TG2474 TSP-17(gt1681) overexpression.
(TIF)
Figure S5 Analysis of tsp-17 behavioral phenotypes. A.
Basal slowing response. Movement before (grey bars)
and after reaching a lawn of bacteria (white bars) is
indicated. B. Quantitative analysis of SWIP behavior in
L1-stage worms, over 20 min. The SWIP phenotype of L1-
stage tsp-17(tm4995) worms is not rescued by cat-2. Assays were
done in triplicate. Error bars represent the standard error of the
mean. C, D. L1 ‘‘swimming-induced lethality’’ pheno-
types. Worms were incubated as for the L4 swimming induced
paralysis assay and plated on seeded plates after the indicated
times to assess viability. Representative pictures are shown in D.
(TIF)
Figure S6 Analysis of 6-OHDA mediated neurodegener-
ation in cat-2, bas-1 and cat-1 strains. Data presented is
from scoring the extent of neurodegeneration 72 h post 6-OHDA
intoxication.
(TIF)
Figure S7 Dopamine receptors act antagonistically to
modulate the 6-OHDA sensitivity of tsp-17(tm4995)
mutants. Worms of the indicated genotypes were intoxicated
with the indicated doses of 6-OHDA and scored 72 h after
intoxication. Experiments were done in triplicate and the average
data is presented.
(TIF)
Figure S8 DAT-1::YFP expression and half live is not
altered in tsp-17(gt1681) mutant worms. A. Expression of
TSP-17 in CEP neurons in wild-type (TG2470) and tsp-
17(gt1681) mutants (TG2471). B. Structural Illumination ‘super
resolution’ images of a CEP dendrite in wild-type and tsp-
17(gt1681) worms showing membrane localization of DAT-
1::YFP relative to a cytoplasmic mCherry marker. There are no
differences in expression. The crosshatching-like pattern is an
artifact introduced by the diffraction grid used in acquisition, not a
feature of expression. Scale bar (white) is 5 mm in length. Images
are 18 mm618 mm. C. Representative FRAP images of DAT-
1::YFP taken prior to bleaching (26 s), immediately after the
bleach event (2 s) and after 2 minutes post bleaching (120 s).
Images are 18 mm618 mm. D. Representative graphs showing
normalized recovery curves in wild-type (top) and tsp-17(gt1681)
(bottom) worms. Example half time of recovery (t1/2) for each
graph is shown at the intersection of the dashed lines. The mobile
fraction is the point at which the curve plateaus. E. Average values
and standard deviation for t1/2 and mobile fractions for DAT-
1::YFP wild-type and tsp-17(gt1681) worms (n= 7).
(TIF)
Figure S9 Dopamine receptors act antagonistically to
modulate the 6-OHDA sensitivity of tsp-17(tm4995)
mutants. Worms of the indicated genotypes were intoxicated
with 10 mM 6-OHDA and scored 72 h after intoxication.
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